{
  "id": "fda_guidance_chunk_0371",
  "title": "Introduction - Part 371",
  "text": "study, alternative procedures used to collect critical safety and/or efficacy data) on the safety and efficacy results reported for the study Robust efforts by sponsors, investigators, and IRBs or IECs to maintain the safety of trial participants and study data integrity are expected, and such efforts should be documented. FDA recognizes that protocol modifications might occur, including unavoidable protocol deviations 7 See 21 CFR 312.30(b) and 812.35(a). Under applicable Federal regulations, investigators who are conducting research with Schedule I controlled substances under the Controlled Substances Act must request prior approval from the Drug Enforcement Administration when seeking to conduct research beyond that which is described in the approved protocol (see 21 CFR 1301.18). Contains Nonbinding Recommendations due to the disaster or PHE, or control measures implemented in response to the disaster or PHE. Efforts to minimize impacts on trial integrity and to document the reasons for protocol deviations will be important. Contains Nonbinding Recommendations APPENDIX: Questions and Answers Q1. Deciding whether to suspend, continue, or initiate trials ......................................................7 Q2. Managing protocol deviations and amendments ...................................................................8 Q3. Submitting changes to IND and IDE protocol.......................................................................9 Q4. Capturing data on protocol and process deviations .............................................................10 Q5. Conducting remote (virtual) clinic visits .............................................................................10 Q6. Remote clinical outcome assessments .................................................................................11 Q7. Use of alternative laboratory or imaging centers ................................................................14 Q8. Use of video conferencing for trial visits ............................................................................15 Q9. Delivering low-risk IPs to home .........................................................................................16 Q10. Disposal of unused IP ..........................................................................................................16 Q11. Changing site for delivering high-risk IP ............................................................................17 Q12. Alternative monitoring approaches .....................................................................................18 Q13. Remote site monitoring visits ..............................................................................................20 Q14. Obtaining informed consent for patients who are physically isolated ................................21 Q15. Collecting electronic signatures and part 11 compliance ....................................................23 Q16. Challenges and temporary waivers for eCTDs ....................................................................24 Q17. Shipping IP to local provider â€’ Form FDA 1572 and accountability .................................25 Q18. Use of commercial versus IPs .............................................................................................26 Q19. Scheduling of meetings with review divisions ....................................................................27 Q20. Postmarketing requirements for drugs, biologics, and devices ...........................................27 Q21. Reporting serious adverse events for approved drugs used to treat conditions related to a disaster or PHE ....................................................................................................................29 Q22. Reporting serious adverse events associated with conditions related to a disaster or PHE in a trial not related to the condition ........................................................................................30 Q23. Exclusion criteria for investigational medical products ......................................................31 Contains Nonbinding Recommendations Q1. What are some of the key factors that a sponsor",
  "source": "FDA_clinical_trial_guidance.txt",
  "section_heading": "Introduction",
  "start_pos": 497280,
  "end_pos": 498816,
  "tokens": 512,
  "tags": [
    "safety",
    "efficacy",
    "design",
    "regulatory",
    "clinical_trial",
    "consent",
    "data"
  ],
  "jurisdiction": "US",
  "document_type": "fda_guidance",
  "guidance_section": "general_guidance",
  "regulatory_weight": "mandatory",
  "created_at": "2025-10-23T02:25:44.705Z"
}